Revolution Medicines Reports Q3 Adjusted EPS
Revolution Medicines reported Q3 adjusted EPS of USD -1.9 versus the IBES estimate of USD -2.41.
Related stories
Albemarle Reports Results for Quarter Ended September 30
M impact | EARNINGS | Nov 05, 2026, 12:07 AM UTC
US Futures Steady After Election Rally
US stock futures were little changed on Thursday after major indexes posted strong gains in the previous session, as a Democratic sweep in the midterm elections triggered a sharp d
H impact | EARNINGS | Nov 05, 2026, 12:06 AM UTC
Motorola Solutions Raises Full-Year Outlook on Strong Demand
Motorola Solutions lifted its annual sales outlook to $13.05 billion from $12.98 billion and also raised its adjusted EPS outlook.
M impact | EARNINGS | Nov 04, 2026, 11:30 PM UTC
Albemarle Q3 Net Sales Beat on Energy Storage Pricing Strength
M impact | EARNINGS | Nov 04, 2026, 11:23 PM UTC
Texas Pacific Land reports Q3 EPS of $2.42
M impact | EARNINGS | Nov 04, 2026, 11:23 PM UTC
Trekor Reports $164 Million in Third-Quarter Adjusted EBITDA
Trekor Metals reported third-quarter 2026 adjusted EBITDA of $164 million.
M impact | EARNINGS | Nov 04, 2026, 11:22 PM UTC